SO-14 Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup — Arndt Vogel (2023) | RDL Network
SO-14 Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
Shukui Qin, Richard S. Finn, Masatoshi Kudo, Tim Meyer, Arndt Vogel, Michel Ducreux, Teresa Macarulla, Gianluca Tomasello, Frédéric Boisserie, Jeannie Hou, Xin Li, James Song, Andrew X. Zhu
Discussion(0)
No comments yet. Be the first to comment.